Cited by 152Substance Abuse Treatment and OutcomesNeurotransmitter Receptor Influence on BehaviorAlcohol Consumption and Health Effects

Medication treatment of different types of alcoholism

Open access
Johnson, Bankole A.·2010·American Journal of Psychiatry

Abstract

Alcoholism remains a serious cause of morbidity and mortality despite progress through neurobiological research in identifying new pharmacological strategies for its treatment. Drugs that affect neural pathways that modulate the activity of the cortico-mesolimbic dopamine system have been shown to alter drinking behavior, presumably because this dopaminergic system is closely associated with rewarding behavior. Ondansetron, naltrexone, topiramate, and baclofen are examples. Subtyping alcoholism in adults into an early-onset type, with chronic symptoms and a strong biological predisposition to the disease, and a late-onset type, typically brought on by psychosocial triggers and associated with mood symptoms, may help in the selection of optimal therapy. Emerging adults with binge drinking patterns also might be aided by selective treatments. Although preliminary work on the pharmacogenetics of alcoholism and its treatment has been promising, the assignment to treatment still depends on clinical assessment. Brief behavioral interventions that encourage the patient to set goals for a reduction in heavy drinking or abstinence also are part of optimal therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2010.08101500

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The psychological or cognitive threat of a DER is thought to be dominant and active and thus dissuade use.

    “To prevent the first drink, however, the psychological or cognitive threat is thought to be dominant and active and thus dissuade use [5], [6], [7].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 9

  1. [5]Johnson BA DiClemente CC Ait-Daoud N Stoks SM Johnson BA Ruiz P Galanter M Brief Behavioral Compliance Enhancement Treatment (BBCET) manual, in Handbook of clinical alcoholism treatment 2003 282 301 Lippincott Williams & Wilkins Baltimore, MD
  2. [8]American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000 American Psychiatric Association Washington, D.C. 4th edition text revision
  3. [45]Hemby SE Johnson BA Dworkin SI Johnson BA Roache JD Neurobiological basis of drug reinforcement, in Drug addiction and its treatment: nexus of neuroscience and behavior 1997 137 169 Lippincott-Raven Philadelphia
  4. [49]National Institute on Alcohol Abuse and Alcoholism Helping patients who drink too much: a clinician's guide, updated 2005 edition 2005 U.S. Department of Health and Human Services Bethesda, MD NIH Publication No. 07-3769
  5. [54]Johnson BA Rosenthal N Capece JA Wiegand F Mao L Beyers K McKay A Ait-Daoud N Anton RF Ciraulo DA Kranzler HR Mann K O'Malley SS Swift RM Topiramate for Alcoholism Advisory Board, Topiramate for Alcoholism Study Group Topiramate for treating alcohol dependence: a randomized controlled trial JAMA 2007 298 1641 1651 17925516
  6. [57]Johnson BA Rosenthal N Capece JA Wiegand F Mao L Beyers K McKay A Ait-Daoud N Addolorato G Anton RF Ciraulo DA Kranzler HR Mann K O'Malley SS Swift RM Topiramate for Alcoholism Advisory Board, Topiramate for Alcoholism Study Group Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment Arch Intern Med 2008 168 1188 1199 18541827
  7. [58]Cruz HG Ivanova T Lunn ML Stoffel M Slesinger PA Lüscher C Bidirectional effects of GABA(B) receptor agonists on the mesolimbic dopamine system Nat Neurosci 2004 7 153 159 14745451
  8. [61]New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) Alpha-baclofen 1999 Data sheet, http://www.medsafe.govt.nz/profs/datasheet/a/alphabaclofentab.htm 10561993
  9. [68]Ait-Daoud N Johnson BA Johnson BA Ruiz P Galanter M Medications for the treatment of alcoholism, in Handbook of clinical alcoholism treatment 2003 119 130 Lippincott Williams & Wilkins Baltimore, MD

Cited by

Sorted by citations

Authors
Johnson, B. A.
Affiliations
University of Virginia (US)
Corresponding author
Johnson, Bankole A.
Venue
American Journal of Psychiatry
Published
2010-06-01
Volume
167
Issue
6
Pages
630-639
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W2142440641
Cited by
151
References
72
Citations by year
2026: 1 · 2025: 1 · 2024: 4 · 2023: 4 · 2021: 2 · 2020: 23 · 2019: 11 · 2018: 3 · 2017: 10 · 2016: 8 · 2015: 10 · 2014: 10 · 2013: 11 · 2012: 31
FWCI
14.89
Type
journal article
Language
en
Open access
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute on Alcohol Abuse and Alcoholism (R01AA010522, R01AA013964, R01AA014628, U10AA011776, R01AA012964)
  • National Center for Research Resources (M01RR000847, M01-RR 00847)
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords
alcoholism, pharmacological treatment of alcoholism, dopaminergic system, ondansetron, naltrexone, topiramate, baclofen, early-onset alcoholism, late-onset alcoholism, binge drinking, pharmacogenetics, brief behavioral intervention, abstinence
MeSH terms
Topiramate, Adult, Aged, Alcohol Deterrents, Alcoholism, Baclofen, Chronic Disease, Depressive Disorder, Female, Fructose, Humans, Hypothalamo-Hypophyseal System, Limbic System, Male, Naltrexone, Pituitary-Adrenal System, Ondansetron, Prefrontal Cortex, Receptors, Dopamine D2, Receptors, GABA, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review